Research Funding

Ongoing Projects

Czech Science Foundation, 23-06558S - Anthracycline-induced DNA damage signaling in the heart: implications for cardiotoxicity development and its pharmacological modulations (2023 – 2025)

Czech Health Research CouncilNW24J-05-00016 - Employment of photosensitizer-based therapy to combat notorious multi-drug resistant bacterial deliquents from the group ESKAPE responsible for skin and wound infections (May 2024 - 2027)

Grant Agency of the Charles University, 1312220 - Study of the effectiveness of (aza)phthalocyanine-based photosensitizers for use in photochemical internalization of biologically active agents (2020, 2024, 2025)

Grant Agency of the Charles University157524 - Development of 3D heterotypic tumor models for the study of photodynamic therapy (2024 - 2025)

ERC-CZ, LL2318 - Smart Photosenzitizers: Highly-Effective, Activatable and Aptamer-Targeted (Sep 2023 - 2025)

Bilateral project Czech Republic - USA in the INTER-EXCELLENCE II program, sub-program INTER-ACTION, LUAUS24335 - Unique isoform-selective topoisomerase II inhibitors as tool for efficient and safe anti-cancer therapy (2024 – 2027)

Johannes Amos Comenius Programme, CZ.02.01.01/00/23_021/0008442 - Pre-application Research of Drugs for Oncological Diseases and for the Prevention and Treatment of Serious Complications (OncoPharm) (2024-2027)

Johannes Amos Comenius Programme, CZ.02.01.01/00/22_008/0004607 - New Technologies for Translational Research in Pharmaceutical Sciences (NETPHARM) (2024 – 2028)

Past Projects

Charles University in Prague:

UNCE 204019/304019/2012 - Research Center for the Study of Toxic and Protective Effects of Drugs on Cardiovascular System (2012 – 2017)

 

Czech Science Foundation (GA ČR):

21-16195S - Chemical biology approach to study anthracycline cardiotoxicity and pharmacological cardioprotection with focus on topoisomerase II beta (2021 - 2023)

19-14758Y - Novel photosensitizers for vascular targeted photodynamic therapy (2019 - Jun 2022)

18-08169S - Study of individual topoisomerase ii isoforms in anticancer and cardiotoxic effects of anthracyclines and their modulations by bisdioxopiperazines (2018 - 2020)

13-15008S - New potential cardioprotective agents: study of structure-activity relationships in various types of myocardial injury (2013 - 2017)

13-27761S - Development of new photosensitizers for photodynamic therapy and investigation of their mechanism of action on cellular
level (2013 - 2016)

GA305/09/0416 - Myocardial damage induced by anticancer drugs and ischemia-reperfusion: new possibilities of pharmacological cardioprotection (2009-2012)

GP305/05/P156 - Study of protective effects of novel iron chelators in the heart injury induced by oxidative stress and anthracycline cytostatics (2005-2007)

GA305/03/1511 – Cardiovascular, potentially cardioprotective and biotransformation effects of novel iron-chelating agents (2003-2005)

 

Grant Agency, Ministry of Health of the Czech Republic (IGA MZ ČR):

NT12403 – Pharmaceutical analysis, study of pharmacokinetics and biotransformation of novel thiosemicarbazone anticancer drugs (2011- 2013)

NT13457 – Anthracycline cardiotoxicity – new possibilities of pharmacological cardioprotection and risks of combination with biologically-targeted anticancer therapy (2012-2015)

 

Grant Agency of the Charles University (GA UK):

1620219 - Complex analysis of biological properties of novel photodynamically active hydrophilic and amphiphilic anionic phthalocyanine derivatives (2019 - 2021)

1916214 - Study of the novel phthalocyanine and azaphthalocyanine photosensitizers for photodynamic therapy of tumors on cellular and molecular level (2014-2016)

299511 - Synthesis and study of antiproliferative effects of novel aroylhydrazone iron chelators (2011-2013)

367911 - Study of cardioprotective effects of novel aroylhydrazone prochelators of iron that are activated by oxidative stress (2011 – 2013)

112409 - Cardiotoxicity of anthracycline drugs: Study of molecular mechanisms of dexrazoxane-afforded cardioprotection; synthesis and initial pharmacological evaluation of its novel analogues (2009-2011)

51308 - Study of the role of free intracellular iron in the pathophysiology of catecholamine cardiotoxicity and possibilities of pharmacological cardioprotection (2008-2010)

124307 - Development of new cardioprotective iron chelators – Synthesis, pharmacological and bioanalytical evaluation (2007-2009)

 

Czech Society of Cardiology:

Study of the role of apoptosis in the anthracycline-induced myocardial damage (2006-2008)

© Charles University, Faculty of Pharmacy in Hradec Králové, Akademika Heyrovského 1203, 500 03 Hradec Králové, Czech Republic
Website information | Powered by Kentico